Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERASE-TMZ
2024-515681-14-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- May 2022
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and irinotecan in colorectal cancer (CRC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Planned start May 2022; status: authorised.
02
Drugs
temozolomideirinotecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-515681-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515681-14-00.